Dianthus Therapeutics' (DNTH) CFO Sold 8,224 Shares for $739,000
Key Points8,224 shares (~$739,000) of common stock were sold on April 9, 2026, at a weighted average price of around $89.84 per share...
Nasdaq News: Markets·9d ago
More News
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Consensus Recommendation of "Buy" from Analysts
Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) has been assigned a consensus recommendation of "Buy" from the fourteen analysts that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, eleven have given a buy recomm...
MarketBeat·13d ago
Dianthus Therapeutics (NASDAQ:DNTH) Sets New 1-Year High - Should You Buy?
Dianthus Therapeutics (NASDAQ:DNTH) Reaches New 12-Month High - Still a Buy...
MarketBeat·14d ago
SG Americas Securities LLC Invests $765,000 in Dianthus Therapeutics, Inc. $DNTH
SG Americas Securities LLC purchased a new stake in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities...
MarketBeat·17d ago
Dianthus Therapeutics (NASDAQ:DNTH) EVP Ryan Savitz Sells 8,224 Shares
Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) EVP Ryan Savitz sold 8,224 shares of the firm's stock in a transaction that occurred on Thursday, April 9th. The stock was sold at an...
MarketBeat·18d ago
Dianthus Therapeutics (NASDAQ:DNTH) Upgraded by Wolfe Research to "Strong-Buy" Rating
Wolfe Research upgraded shares of Dianthus Therapeutics to a "strong-buy" rating in a research note on Wednesday...
MarketBeat·18d ago
Wolfe Research Begins Coverage on Dianthus Therapeutics (NASDAQ:DNTH)
Wolfe Research initiated coverage on shares of Dianthus Therapeutics in a research note on Thursday. They set an "outperform" rating and a $98.00 target price for the company...
MarketBeat·19d ago
Dianthus Therapeutics (NASDAQ:DNTH) Sets New 12-Month High - Time to Buy?
Dianthus Therapeutics (NASDAQ:DNTH) Reaches New 52-Week High - What's Next...
MarketBeat·20d ago
Dianthus Therapeutics CFO Sells $9.5 Million in Stock
Key Points114,367 shares were sold for a transaction value of approximately $9.49 million on March 31, 2026...
Nasdaq News: Markets·22d ago
JPMorgan Chase & Co. Has $2.68 Million Stock Position in Dianthus Therapeutics, Inc. $DNTH
JPMorgan Chase & Co. lifted its stake in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 626.4% during the third quarter, according to the company in its most recent filing with...